NEW YORK, May 15, 2014 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com) is investigating potential claims against the board of directors of Gentiva Health Services, Inc. ("Gentiva" or the "Company") (NASDAQ: GTIV) concerning the proposed acquisition of the Company by Kindred Healthcare Inc. ("Kindred").
On May 13, 2014, the Gentiva Board of Directors rejected an unsolicited acquisition offer by Kindred worth approximately $533 million in cash and stock, or approximately $14 per share. According to correspondence between the two companies, Gentiva also rejected a $13 per share offer from Kindred in April.
Bloomberg news reported that an analyst with CRT Capital Group LLC stated that it is "a mistake for the board not to enter negotiations."
Our investigation concerns whether the Gentiva board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company shareholders.If you own Gentiva shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact: Benjamin I. Sachs-Michaels, Esq. Robert I. Harwood, Esq.Harwood Feffer LLP488 Madison Avenue New York, New York 10022Phone Numbers: (877) 935-7400(212)935-7400Email: firstname.lastname@example.org Website: http://www.hfesq.com Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website ( http://www.hfesq.com) for more information about the firm. Attorney Advertising © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP ( www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO SOURCE Harwood Feffer LLP
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV